In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

INSYS Therapeutics, Inc.

http://www.insysrx.com

Latest From INSYS Therapeutics, Inc.

Minute Insight: Current Testing Technologies Can Detect The Omicron Variant

As fears about vaccine escape grow, test manufacturers have been quick to assert that their tests can spot the new Omicron variant of SARS-CoV-2

In Vitro Diagnostics Diagnostics

Finance Watch: CF Foundation Commits $110m In Partnership With Flagship’s Pioneering Medicines

Private Company Edition: Flagship’s Pioneering Medicines initiative and the firm’s portfolio companies will deliver cystic fibrosis drug candidates. Also, recent venture capital financings include cloud technology firm Saama’s $430m round and Shoreline’s $140m in new funding.

Financing Innovation

Agenus PD-1 Down But Not Out With Cervical Cancer BLA Withdrawal

The company announced it would withdraw the BLA for balstilimab monotherapy in cervical cancer following Keytruda’s full approval, but it plans to keep developing the drug.

FDA ImmunoOncology

COVID-19: FDA Tells Test Makers How To Minimize Effects Of Variants

The US Food and Drug Administration has taken additional steps to ensure mutations of the COVID-19 virus do not negatively impact the efficacy of tests.

FDA Coronavirus COVID-19
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
  • Other Names / Subsidiaries
    • NeoPharm, Inc.
    • Fresenius Biotech GmbH
    • Neovii Biotech GmbH
UsernamePublicRestriction

Register